Dr. Robert Lazarus Modlin, MD

Dr. Modlin practices at Ronald Reagan UCLA Medical Center in Los Angeles, California, part of University of California Health.

Dr. Modlin's NPI, 1558395160, was assigned on July 10, 2006. Dr. Modlin graduated from New York University School of Medicine in 1980. Dr. Modlin's California license number on file is G46803.

Dr. Modlin's primary practice is Ronald Reagan UCLA Medical Center, at 757 Westwood Plaza, Los Angeles, CA 90095 in Los Angeles County. The practice phone is (310) 825-6301.

Dr. Modlin's primary practice is Ronald Reagan UCLA Medical Center in Los Angeles, California, part of University of California Health. The medical group on file is UCLA Medical Group. Dmand AI also links Dr. Modlin to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Modlin practices, 3 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Modlin's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Modlin is board certified in dermatology by the American Board of Dermatology. Dr. Modlin has a license on file in California.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, itchy rashes, scalp rash and skin cyst among the conditions Dr. Modlin treats.

CMS data shows 144 Medicare services from Dr. Modlin across 4 procedure codes in 2024, for 52 Medicare patients. Medicare paid $4,498 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 52 Medicare patients who saw Dr. Modlin in 2024. The largest group is 75 to 84, with 20 patients. 75% of them have high cholesterol, and 71% have high blood pressure. 27% are also on Medicaid. Their average risk score is 1.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Modlin's median patient age at 68, with 46% women.

In 2024, Dr. Modlin wrote 59 Medicare Part D claims for 22 patients. 100% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $657 in total drug cost. In 2023, CMS named 26 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Modlin for performance year 2024, reported as part of a group. Dr. Modlin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 23 procedures of removal of skin lesions by Dr. Modlin, more than 66% of the clinicians it reports for that procedure.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 30 papers to Dr. Modlin, published from 2013 to 2025. 2018 was the busiest year, with 5. The most frequent topics are Inflammation. Dr. Modlin's most frequent co-authors are Michel Francois Gilliet, MD, Philip Oliver Scumpia, MD and Emanual Michael Maverakis, MD.

Dmand AI links Dr. Modlin to 1 clinical trial. Conditions studied include Vitamin D Deficiency and Avitaminosis.

CMS Open Payments shows 1 general payment to Dr. Modlin from 1 drug or device company in 2022. Consulting fees make up the largest share, 100% of the total. Pfizer Inc. paid the most, $2,500.

Dmand AI lists 4 awards for Dr. Modlin, most recently ASCI Member in 2013.

Dr. Modlin graduated from New York University School of Medicine in 1980. Dr. Modlin is a member of AAD.

Dr. Modlin is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.